Brendan Connors and his oncologist Dr. Michael Postow of Memorial Sloan Kettering discuss the importance of communication between patient and doctor throughout immunotherapy treatment.
Dr. Michel Sadelain of Memorial Sloan Kettering highlights a revolutionary new treatment approach—CAR T cell immunotherapy—that he helped pioneer.
Dr. Patrick Hwu of the MD Anderson highlights the promise and potential of combination immunotherapies and how biomarkers can be used to guide these strategies.
Dr. Elizabeth M. Jaffee of Johns Hopkins University discusses cancer immunotherapy’s ongoing efforts to overcome the challenges ahead and enable immunotherapy to benefit even more people with cancer.
Caregivers Casey Zmudzinski and Benny Juarez, and cancer veteran Kristin Kleinhofer, discuss how they advocate for the best care possible for their loved ones.
Dr. Matthew Hellmann of Memorial Sloan Kettering Cancer Center discusses new FDA approvals, clinical trials, and potential treatments for patients with small cell lung cancer.
Dr. Rony Dahan of Weizmann Institute of Science (Israel) discusses the latest advances in targeted antibodies for the effective treatment of many forms of cancer.
Two cancer patients—Stephen Estrada and Mary Elizabeth Williams—discuss how they regained control after their cancer diagnosis
Dr. Gavin Dunn of Washington University in St. Louis discusses how cancer vaccines are capable of educating patients’ immune systems and have the potential to improve the immune system’s ability to target and eliminate cancer.
Dr. Kunle Odunsi of the Roswell Park Comprehensive Cancer Institute discusses how biomarkers are used to help patients today as well as how we’re working to harness the full potential of biomarkers moving forward.
Dr. Philip Greenberg of the University of Washington discusses how cutting-edge strategies using T cells from patients’ blood are currently being used in the clinic as well as how they might be improved moving forward.
Ariella Chivil, a patient advocate, and Dr. Alexander M. Lesokhin, her oncologist, discuss the nuances of communicating and informing both doctor and patient while on immunotherapy.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last week.
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers, and cellular immunotherapy.